Literature DB >> 6037393

Hypnotic properties of mebutamate: a comparative study of mebutamate, secobarbital and placebo in psychiatric patients.

L Tetreault, P Richer, J M Bordeleau.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1967        PMID： 6037393      PMCID： PMC1923261     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN： 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  6 in total

1.  Mebutamate as antihypertensive agent in hospital outpatients.

Authors:  A C CORCORAN; H F LOYKE
Journal:  JAMA       Date:  1962-09-22       Impact factor: 56.272

2.  The hypnotic effect of a new propanediol dicarbamate, W 583 (a double blind, double dose study).

Authors:  T BODI; H A LEVY; J H NODINE; J H MOYER
Journal:  Am J Med Sci       Date:  1960-02       Impact factor: 2.378

3.  CLINICAL EVALUATION OF A NEW ANTIHYPERTENSIVE AGENT: W583 (MEBUTAMATE).

Authors:  D A KAVELMAN; J A LEWIS
Journal:  Can Med Assoc J       Date:  1963-11-09       Impact factor: 8.262

4.  The pharmacological properties of 2-methyl-2-sec-butyl-1,3-propanediol dicarbamate (Mebutamate, W-583), a new centrally acting blood pressure lowering agent.

Authors:  F M BERGER; J F DOUGLAS; M KLETZKIN; B J LUDWIG; S MARGOLIN
Journal:  J Pharmacol Exp Ther       Date:  1961-12       Impact factor: 4.030

5.  Observations on the antihypertensive effectiveness of a new propanediol dicarbamate (W-583).

Authors:  C DUARTE; A N BREST; R KODAMA; F NASO; J H MOYER
Journal:  Curr Ther Res Clin Exp       Date:  1960-05

6.  Clinical observations on the antihypertensive response to mebutamate (Capla) in geriatric patients.

Authors:  G A PORTER; M D BAIRD; H E GRISWOLD
Journal:  Am Heart J       Date:  1962-06       Impact factor: 4.749
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.